

A TRANSFORMING PARADIGM: CERAMIDE-RICH PLATFORMS

Scientific evidence demonstrates Ceramide-rich Platforms (CRPs) to be a novel therapeutic target relevant to oncology and T-cell mediated autoimmunity.

SALSS CONTACT

Chuck Dimmler
Chief Executive Officer

chuck@ceramedix.com
+1 (917) 224-8067

Ceramedix Holding LLC
555 Madison Ave Ste 1201
New York, New York 10022-3328
United States

www.ceramedix.com

Ceramedix

CERAMEDIX HOLDING LLC | PRIVATELY OWNED

Founded in 2015, Ceramedix is an early stage cancer and auto-immune disease company focused on commercializing broad therapeutic applications of fundamental cell-signalling discoveries at Memorial Sloan Kettering Cancer Center (MSKCC).

OUR PRODUCTS & SERVICES

The inability to control the balance between cell proliferation and apoptosis remains a crucial challenge in the management of cancer and autoimmune disease.

Ceramedix addresses this unmet need through its development of a transformative therapeutic approach based upon the role of CRPs,

In response to chemotherapy and radiotherapy, as well as cytotoxic T lymphocytes (CTLs), raft-like structures known as ceramide-rich platforms (CRPs) form rapidly on cell membranes. CRPs signal cell injury and death.

- Enhancing CRP formation increases chemotherapy and radiation tumor response.
- Inhibiting CRP formation protects against tissue damage.

Ceramedix owns an exclusive license from Memorial Sloan Kettering Cancer Center to reduce this proprietary know how to commercial practice.

WHAT MAKES US UNIQUE

The CRP signaling pathway is unique and ubiquitous. Targeting CRPs is a transforming paradigm, offering a powerful new method to impact the viability of cells.

The company's scientific founders are the leading experts in this space, with keen proprietary insight into novel therapeutic interventions involving CRPs.

Ceramedix exclusive license to this extensive patent estate provides a robust foundation upon which to convey this therapeutic paradigm ultimately to the clinic.

WHY YOU SHOULD MEET US

Ceramedix is seeking multiple development partnerships in three therapeutic areas:

- Oncology: Anti-angiogenics
- Acute GvHD: h2A2 Antibody
- Autoimmunity: scFv

KEY TEAM

Chuck Dimmler III

- CEO & Director
- Vice Chairman, Torrey Advisors, NY
- Former CEO of Lundbeck US and Chief Investment Officer of H. Lundbeck A/S

Zvi Fuks MD

- Chief Medical Officer
- Internationally renowned physician-scientist in radiation oncology
- Former Chair, Department of Radiation Therapy, MSKCC

Richard Kolesnick MD

- Chair, Advisory Board
- Head, Laboratory of Signal Transduction, Sloan Kettering Institute
- Internationally renowned expert on role of the Sphingomyelin Signaling Cascade and its secondary messenger, ceramide, in radiation- and chemotherapy-induced vascular injury and tissue damage

**SWEDISH
AMERICAN
LIFE SCIENCE
SUMMIT
2017**